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Several molecular elements of programmed celi death and apoptosts have recently been revealed. The function of gene products which deliver the 
lethal ‘htt’ IS still not known. Well-characterized and newly discovered cell surface structures (e.g. antigen receptors, FASIAPO-I), as well as 
transcripttonal factors (steroid receptor, c-ma. P53. retmoblastoma protein and others), have been implicated m the initiation of the death pathway. 
Negative regulators of the process (ceci-9 gene product in programmed death of cells m C/uzenorhabdms elegans and bcl-2 protein m apoptosis) 
have been described. Brochemical mechanisms responsible for the silent nature of natural deaths of cells include their rapid engulfment (mainly 
through mtegrm receptors). transglu~~minase-catalyze cross-lmking of cellular proteins, and fragmentation of DNA. Several lines of evidence 
suggest that distinct molecular mechanisms may operate in various forms of natural ceil death. 
Lethal swatch: Death control: Negative regulator; Silent removal: Dtstmct form 
1. INTRODUCTION 
The intense genetic, biochemical and cellular studies 
of recent years have revealed the existence of a basic. 
evolutionarily conserved mechanism of regulated cell 
death which usually occurs under physiolo~cal condi- 
tions and is often programmed [l-3]. It is generally 
agreed that a cascade of genes must be expressed in 
order for the cells to die. During evolution, the death 
program has been modified in a cell- and tissue-specific 
manner to accomplish a number of physiological func- 
tions. These include elimination of cells that (i) have no 
function, (ii) generated in excess. (iii) develop improp- 
erly, (iv) have already completed their lifespan or (v) are 
harmful [ 11. and (vi) production of dead cells for specific 
function (e.g. cornification and lens cells [3]). Genetic 
analysis in Caenorhabditis elegans, in which one of eight 
nuclei generated in the normal lineage of the hermaph- 
rodite is fated to die (always the same cells at the same 
time of development), has identified several genes that 
function in normal death [I]. The biochemical function 
of the products of these genes is not known. However, 
a number of biochemical events have been observed 
during apoptosis 13.41, a natural death phenomenon 
originally described in mammalian cells by morpholog- 
ical criteria [2,5]. The combined evaluation of recently 
acquired molecular data points to critical elements of 
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programmed cell death. as well as apoptosis. and sug- 
gests that diverse biochemical pathways may lead to the 
ultimate fate of cells. 
2. THE LETHAL SWITCH 
The existence of killer gene products has been clearly 
shown in C. elegans where the loss of ted-3 and ted-4 
activity allows cells, which normally die, to live [ 11. The 
normal products of these genes, which act within the 
cells themselves. must activate programmed cell death 
or participate directly in the killing. According to DNA 
sequences they are novel proteins; the ted-$-encoded 
one contains two sites similar to the Ca*‘-binding EF- 
hand motif [6], and the ted-3 protein contains many 
serine residues in motifs similar to known phosphoryla- 
tion sites [l]. Neither the regulation nor the biochemical 
activity of these proteins has been determined yet. 
Chromatin fragmentation into oligonucleosomal 
length fragments (which appear as a ‘ladder’ after DNA 
electrophoresis) by a non-lysosomal Ca”/Mg”-de- 
pendent endonuclease (which is constitutively expressed 
in almost all types of cells) has long been considered to 
be the hallmark, and potentially even the initiating 
mechanism, of apoptosis [7]. However, in C. elegans, 
genes for cell death are clearly separable from, and act 
prior to, an endonuclease (the product of the rtuc-I 
gene) which acts in cells engulfing and degrading the 
dead cells [I]. In three other instances of programmed 
cell death the activation of an endonuclease has been 
shown to be neither a trigger nor a necessary or defining 
component of the early phase of death [S]. Similarly. 
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condensation of the chromatin at the membrane of ap- 
optotic nuclei, an early morphological sign of apopto- 
sis, have not been found associated with activation of 
an endonuclease [9,10], and several types of cells un- 
dergo apoptosis without DNA fragmentation [ll]. It 
has recently been demonstrated that the Ca”/Mg’‘-de- 
pendent endonuclease is functionally and antigenically 
identical to DNase I [12]. It has been suggested that, in 
addition to increased intracellular Ca’+ levels, lamin 
phosphorylation and solubilization, and breakdown of 
the nuclear envelope, are early events in cell death, al- 
lowing the rapid access of activated endoplasmic reticu- 
lum enzymes, such as the DNase I, to the nucleus. The 
well-known actin-DNase I interaction might be of 
physiological relevance during mitosis and apoptosis; 
whereas the free DNase I is kept inactive during the 
nuclear membrane breakdown in normal cell cycle by 
G-actin, this control may be impaired during cell death. 
It should be noted that there are reports suggesting that 
apoptosis is actually linked with DNA structural degra- 
dation of one strand [13] and that selective cleavage of 
28 S rRNA variable regions is one of the critical ele- 
ments of apoptosis [14]. 
The elusive nature of the killer gene products makes 
studying their regulation and control difficult. In most 
of such studies DNA fragmentation, which now seems 
to be neither a specific nor a critical event of the process. 
has usually served as the quantitative and/or qualitative 
measure of apoptosis or even programmed cell death. 
Nevertheless, a number of initiating mechanisms are 
now known. Binding of ligands, such as transforming 
growth factor p,, antigen and tumor necrosis factor 
(TNF), to their respective cell surface receptors initiates 
apoptosis in appropriate cell types (for references see 
[3]). FASIAPO-I is a transmembrane member of the 
TNF receptor family that mediates apoptosis [ 15,161; its 
expression on target cells is necessary for them to be 
killed by cytotoxic T cells [17], and its mutation leads 
to autoimmune disease [16]. A significantly conserved 
novel protein domain at the cytoplasmic region of the 
FASIAPO-I antigen and type 1 TNF receptor seems to 
transduce the apoptotic signal into susceptible cells [ 181. 
The signal pathways (which may include Ca’+, CAMP, 
protein kinase C, phosphatases and kinases other than 
protein kinase C [3,4,19,20]) and the molecular details 
of the transcriptional response of cells to receptor stim- 
ulation. vary from one cell/receptor type to the other. 
It is determined by the maturation and differentiation 
status of the cell, i.e. how much they are competent and 
primed for apoptosis [3,4]. 
Glucocorticoids, retinoic acid and thyroxin induce 
apoptosis in susceptible cells through the transacti- 
vating potential of their respective nuclear receptors 
[2,3]. The c-nzyc proto-oncogene, usually implicated in 
cell transformation, differentiation and cell cycle pro- 
gression, also has a central role in some forms of apop- 
tosis. The c-myc gene product, when over-expressed in 
2 
cells deprived of growth factors [21] or treated with heat 
[22], induces apoptosis and inhibition of c-nryc expres- 
sion with anti-sense oligonucleotide prevents activation- 
induced death of T cell hybridomas [33]. There is evi- 
dence that the T cell activation-induced transcriptional 
factor Ap-Z (homo- or heterodimer of members of the 
Jun and Fos family) is involved in programmed cell 
death [24,25]. The continuous expression of c-fbs at sites 
of naturally occurring cell death of f&-lucZ transgenic 
mice, beginning hours or days before the morphological 
demise of the cell, appears to be a hallmark of terminal 
differentiation and a harbinger of death [26]. Over-ex- 
pression of the wild-type ~53 anti-oncogene product 
could induce apoptosis in cultured cells [27], and thy- 
mocytes from strains of ~53 ‘knock-out’ mice are ex- 
traordinarily resistant to the induction of the process by 
radiation and topoisomerase II inhibitors [X3,29]: in- 
tranuclear p.53 accumulates following DNA damage, 
and this is part of the lethal signal. Mice deficient in the 
retinoblastoma oncosuppressor gene show accentuation 
of the normal tissue patterns of apoptosis. particularly 
in the central nervous system, which leads to the death 
of these animals in utero (Andrew Wyllie, personal 
communication). The well-known activity of all of these 
proteins in transcriptional regulation points to their in- 
volvement in turning on, and modulation of, one or 
more ‘lethal’ genes: the identity of such genes and their 
relationship to cell death events is completely unknown. 
3. CONTROLLING DEATH 
There is increasing evidence to suggest that most an- 
imal cells are capable of killing themselves [1,30.31]. 
Since the program of self-elimination is built into the 
biochemical machinery of cells it should be tightly con- 
trolled. Cells require survival signals to stay alive. These 
signals are provided by survival factors acting on cell 
surface or nuclear receptors (growth factors, antigens, 
hormones, cytokines. bacteria; see [3,31]) and by differ- 
entiation. Survival of most mammalian cells is tempo- 
rary since only a few types live throughout the lifetime 
of the organism. What is the biochemical explanation 
of cell survival? 
Since the regulation of the putative death switch 
seems to be mainly transcriptional (see above), one may 
expect that its control is accomplished at the same level, 
and the induction of cell death by either limitation of 
survival factors or by the appearance of apoptotic fac- 
tors leads to down-regulation or over-riding of the mo- 
lecular blockers of cell death initiation. Very little is 
known about the biochemical nature of these events. 
One of the most dramatic developments of the last 
2-3 years in cell death research is linking the function 
of hcl-2 proto-oncogene to negative regulation of apop- 
tosis. First, it was shown that after introducing bcl-2 
into cells and then cutting off the cytokine supply, the 
cells survived even though they were supposed to die 
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[32]. Then, transgenic mice were made bearing the bcl-2 
oncogene in B cells and showed extended survival of 
these cells [33]. It looks as if bcl-2 is a kind of antidote 
to apoptosis and programmed cell death; (i) hcl-2 pro- 
tein is topographically restricted to long-lived or prolif- 
erating cell zones in tissues that demonstrate apoptotic 
cell turnover [34]. (ii) expression of the human hcl-2 
gene in C. elegans reduced the number of programmed 
cell deaths [35], (iii) over-expression of the bcl-2 protein 
in cultured sympathetic neurons prevents apoptosis 
normally induced by deprivation of nerve growth factor 
[36], and (iv) the c-nzl,c-induced forms of cell death are 
prolonged when bcl-3 is over-expressed [22]. At present, 
nothing is known about the function of the bcl-2 pro- 
tein, which has been detected in the mitochondrial mem- 
brane and also in the nuclear envelope and endoplasmic 
reticulum. Of interest is the finding that the first 195 
amino acids of bcl-2 is sufficient for function. provided 
that a heterologous membrane-associated domain is at- 
tached [37]. One recent development that may help clar- 
ify bcl-2’s function comes from C. elegans studies; a 
gene called ted-9, which appears to be the C. eleguns 
equivalent of bcl-2, has been identified [30]. Its ‘gain of 
function’ form of mutant prevents all programmed cell 
deaths (that is the activity of ted-3 and ted-4). and the 
loss of the activity of this gene leads to early develop- 
mental death of the organism. 
There are a number of additional biological and bio- 
chemical observations related to prolonged survival of 
cells. The absence of bcl-2 from tissues (e.g. the liver) as 
well as cell types (e.g. endothelial and smooth muscle 
cells) with regular turnover [34] and the regulated occur- 
rence of bcl-2-independent forms of apoptosis (i.e. 
which occur in the presence of even over-expressed bcl-2 
protein; see next paragraph) suggest the existence of 
redundant inhibitor elements. Apoptosis has been pre- 
vented by down-regulation or, in other types of cell, by 
activation of protein kinase C [38,39]. It is inhibited by 
L-acetylcarnitine [40], by tumor promoters [41], through 
inhibition of the calcineurin (serine/threonine phosphat- 
ase 2B) by cyclosporine [42], and after induction of 
sustained elevation of cytoplasmic calcium [43]. The 
biochemical target(s) of these effects and their relation- 
ship to bcl-2 expression or function is presently not 
known. 
4. WHAT MAKES NATURAL CELL DEATH SI- 
LENT? 
A distinctive feature of natural cell death is that de- 
spite the dramatic morphological changes (which often 
include fragmentation and formation of membrane lim- 
ited particles) the cells are removed without any leakage 
of intracellular components and without the induction 
of the inflammatory response and scar formation. The 
dead cells are recognized and ingested while still intact, 
protecting tissues from the potentially harmful conse- 
quences of exposure to the contents of the dying cell. At 
least three phagocytosis recognition mechanisms. which 
do not lead to release of phlogistic agents. such as 
eicosanoids or cytokines, have been identified in vitro 
(reviewed in [44]). The use of the CI,/& vitronectin recep- 
tor integrin and thrombospondin by a number of mac- 
rophages seems to be complemented by receptors recog- 
nizing carbohydrate changes and exposed phosphati- 
dylserine on apoptotic cells. The existence of multiple 
phagocyte recognition mechanisms for apoptotic cells 
is not unexpected in view of the number of genes in- 
volved in removal of cells undergoing programmed cell 
death in C. ekgans. Indeed, the observation that the 
biggest defects in removal of dying cells occur in double 
mutants (firstly in c&-2, ted-5 or ted-ZU with a second 
mutation in one of ted-1, ted-6. ted-7 or ted-8) has 
prompted the suggestion that there might be distinct, 
parallel recognition processes which are partially redun- 
dant [l]. 
The swift and efficient engulfment of dead cells is only 
one of the critical elements which ensure that macro- 
molecules are not released from the dying cells provok- 
ing an inflammatory/immune response. Cross-linking 
of intracellular proteins by the Ca”-dependent tissue 
transglutaminase. which is induced and activated in a 
wide variety of cells undergoing apoptosis or pro- 
grammed cell death both in vivo and in vitro [3], leads 
to the formation of a protein shell in apoptotic cells and 
bodies [45]. Blocking the induction of the enzyme in 
dying cells by either antisense oligonucleotides or inhib- 
itors results in increased leakage of DNA and protein 
molecules. Its over-expression. depending upon the in- 
tracellular level of the enzyme, leads to increased adhe- 
sion to extracellular matrix, higher rate of cell death, 
apoptotic fragmentation of the cytoplasm and de- 
creased rate of macromolecular leakage during TNF- 
induced cell death ([46], author’s unpublished observa- 
tions). DNA degradation by DNase I, the physiological 
epiphenomenon occurring in most apoptotic cells, may 
also serve to limit release of potentially dangerous ge- 
netic material (which may even stimulate production of 
autoantibodies) spreading from the dying cells: The 
functional significance of the association between 
clusterin (SGPP-2ITRPM-2) and apoptosis, which oc- 
curs in several cell death settings, may be related to 
tissue protection [47]. Clusterin may provide protection 
to the dying cells from complement attack or a mecha- 
nism to rid the tissues of apoptotic bodies by targetting 
them into lipoprotein particles. 
5. DISTINCT FORMS OF NATURAL CELL 
DEATH 
Based on morphological observations it has been sug- 
gested that perhaps all programmed cell death, and even 
all forms of natural cell death, occurred via apoptosis 
[2,5]. Detailed examinations and comparison of pro- 
3 
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grammed cell death in C. elegans, in the moth Manduca 
sexta, in neurons and apoptosis of various cell types 
(thymocytes, hepatocytes, etc.) showed that they differ 
in terms of cell surface morphology, nuclear ultrastruc- 
ture, DNA fragmentation, and polyubiquitin gene ex- 
pression [l.l 11. It is also clear, now, that fragmentation 
of DNA into oligonucleosomes is usually a late event 
and it does not occur in all forms of programmed cell 
death or even apoptosis (see above). As molecular char- 
acterization of the process has been progressing more 
and more, data indicate the existence of distinct molec- 
ular forms of natural cell death. 
There are apoptosis forms, which take place irrespec- 
tive of the presence of high intracellular levels of bcl-2 
protein. These death forms include the elimination of 
self-reacting T cells by negative selection [48]. mIgM 
cross-linking-mediated apoptosis of immature WEHI- 
231 cells ([49]; an accepted model for elimination of 
autoreactive B lymphocytes), apoptosis induced by 
withdrawal of 11-2 or IL-6 [32], by cytotoxic T cells [50] 
or by TNF or by antibodies raised against the FAST 
APO-I self-surface protein. Similarly, the programmed 
death of some C. elegans cells (e.g. the male linker cells 
which fail to die when neighbouring cells are ablated) 
does not occur by a mechanism that can be inhibited by 
ted-9 [I]. These observations suggest that either distinct 
forms of cell death exist or that the death pathway is 
accessible at points proximal, as well as distal, to the 
biochemical function of bcl-Zlced-9. 
Thymocytes prepared from mice constitutively ho- 
mozygous for deletion in the p53 gene are resistant to 
induction of apoptosis [28,29] by radiation or etoposide 
(an inhibitor of topoisomerase II). However, they retain 
normal sensitivity to glucocorticoid or the combination 
of calcium ionophore and the protein kinase C activa- 
tor, PMA. The latter reproduces many features of thy- 
mocyte death involved in the physiological process of 
negative selection, which is bcl-2-independent [48]. Cal- 
cium-dependent activation and glucocorticoid some- 
times exert mutually antagonistic effects on thymocyte 
apoptosis [51], and the regulatory role of c-myc exists 
only in the former [23]. Nuclear proteins egr-1 and apt-2 
show up in T cells undergoing activation-induced death 
but not in cells dying after glucocorticoid treatment. 
These results suggest that the p.53-independent pathway 
may itself be very complex, and stimuli which cause 
apoptosis in thymocytes in the absence of p.53 function 
may use other transcriptional factors to activate the 
same set of cell death genes. 
Most cell death forms, either dependent or independ- 
ent of either bcl-2 or ~53 are delayed or abrogated by 
inhibitors of RNA and/or protein synthesis. However, 
it has been also demonstrated in in vitro experiments 
that apoptosis could proceed or be potentiated in the 
presence of these compounds, and there are also cases 
(especially rapidly proliferating cultures of malignant 
cells) where apoptosis can be directly triggered by the 
4 
inhibitors [52,53]. Whether these findings reflect distinct 
forms of apoptosis or variations on a single pathway is 
not yet known. Interestingly, the hcl-2-independent 
death of target cells induced by cytotoxic T cells does 
not require de novo protein synthesis [53]. On the other 
hand, bcl-2 protects cells from a wide range of non- 
physiological stimuli. such as azide. colchicine. heat 
[50], which are independent of protein synthesis. It is 
also possible that, in some of the cells showing apopto- 
sis in response to protein synthesis inhibitors, the death 
machinery is already set, but is being actively sup- 
pressed by short-living protective proteins [53,54]. Al- 
ternatively, some of these adverse effects can be ex- 
plained by the constitutive expression and drug-induced 
activation of DNase I: in rapidly proliferating cells the 
breakdown of the nuclear membrane and the internucle- 
osomal degradation of exposed DNA may lead to the 
development of apoptosis-like morphology and DNA 
degradation pattern without the presence and involve- 
ment of the complete machinery of natural cell death. 
In any case, the recognizable and reproducible patterns 
of gene expression that correlate morphological 
changes in involutioning tissues and during pro- 
grammed death-mediated embryonic remodelling [l- 
4,8,24,41,55] strongly favour the understanding that ac- 
tive gene expression with protein synthesis is an essen- 
tial part of the natural cell death program in living 
tissues. 
Little attention has been paid to natural cell death 
forms which produce cells temporarily arrested in one 
stage of the death program for specific physiological 
functions. Lens epithelial cells. red blood cells and ter- 
minally differentiating keratinocytes undoubtedly rep- 
resent distinct and specialized forms of natural cell 
death which, however, are evolutionarily related to, and 
share common elements with, apoptosis or pro- 
grammed cell death [3]. For example, the death and 
cornification of keratinocytes. which is initiated by an 
unknown signal mechanism and transcriptional factors, 
is controlled by bcl-2, is triggered by calcium influx. 
leads to nuclear disintegration through internucleo- 
somal DNA degradation, involves transglutaminase- 
catalyzed cross-linking of proteins to encapsulate cells 
in a highly cross-linked protein envelope and is regu- 
lated by glucocorticoids and retinoids [56]. 
6. PERSPECTIVES 
During the last 2-3 years cell death studies have rap- 
idly moved into the main focus of biomedical research. 
Genetic and cell biology observations have outlined the 
major issues, and the obvious clinical as well as pharma- 
cological implications have created almost unprece- 
dented interest. The application of the many tools of 
biochemistry and molecular biology is just beginning. 
Functional analysis of gene products related to cell 
death will lead to understanding. then possibly to phar- 
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macological control of the process. At present the most 
challenging tasks are to find the killer genes/proteins, to 
clarify their biochemical function and to understand 
how signals are transmitted to and from them. The 
discovery of novel proteins and/or principles may be 
needed to link the function of the revealed cell death- 
related transcriptional factors to effector elements of the 
cell death process. The comparative and detailed analy- 
sis of the many in vivo and in vitro model systems will 
clarify how many distinct and perhaps redundant or 
overlapping molecular forms of natural cell death exist, 
and how much their cell- and tissue-specific manifesta- 
tions differ. 
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